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EUPATI 2013 CONFERENCE 
EUPATI: A VISION FOR 2020 
19 April 2013, Hilton Rome Airport Hotel, Rome Airport Fiumicino, Italy 
 
Introduction 
The EUPATI consortium is delighted to announce its first EUPATI conference entitled “EUPATI: A Vision for 
2020”. 
We are looking to the future: 2020 and three years beyond the end of the project, to how tools and knowledge 
provided through EUPATI could make a difference to patients advocates, patient organisations and the public. 
We want this conference to focus on ‘real world’ healthcare hot topics which you, as conference delegates, could 
relate to. 
The conference programme has been structured around three key topics: patient involvement in medicines research 
and development; building competences and knowledge in medicines R&D; increasing the public awareness of 
benefits and risks of new treatment development. 
Short presentations are designed to inspire a collective vision.  Using actual examples we will bring to life existing best 
practices, discuss future patient involvement and empowerment within medicines development and demonstrate how 
the Patients’ Academy would add value and bring great benefit. 
Together, through the EUPATI lens the conference sets out to explore: 
o What would patient involvement in medicines development look like in 2020?  
o How can we build knowledge & competences for patients’ involvement in medicines R&D?  
o By 2020 what increase will we predict in public knowledge about development of new treatments? 
We want each conference delegate to participate in shaping and building this vision. Throughout the conference you 
will have many opportunities to voice your opinions and share your thoughts. Open and active dialogue is strongly 
encouraged.  
At the end of the day we hope each conference delegate will: 
o understand the value of courses, materials and information currently being developed by EUPATI 
o see how these different resources can be applied to shape the future of medicines development  
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Faculty 
Nicola Bedlington European Patients’ Forum (EPF), Belgium 
Dave Bryant  Luto Research, United Kingdom 
Filippo Buccella  Parent Project Onlus, Italy 
Virginie Delwart Janssen, Belgium 
Rebecca Dickinson University of Leeds, United Kingdom 
Jan Geissler  European Patients’ Forum (EPF), Germany 
Michel Goldman Innovative Medicines Initiative (IMI) 
Matthias Gottwald Bayer Pharma, Germany 
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David Haerry  European Aids Treatment Group (EATG), Switzerland 
Nancy Hamilton European Organisation for Rare Diseases (EURORDIS), France 
Ingrid Klingmann European Forum for Good Clinical Practice (EFGCP), Belgium 
Svilen Konov  European Aids Treatment Group (EATG), Belgium 
Paola Mosconi Istituto di Ricerche Farmacologiche Mario Negri, Italy 
Jennifer Newman NIHR Medicines for Children Research Network, United Kingdom 
Peter O’Donnell Journalist, Belgium 
Anders Olauson European Patients’ Forum (EPF), Sweden 
Lucy Simons  INVOLVE /University of Leeds, United Kingdom 
Soren Skovlund Novo Nordisk, Denmark 
Bella Starling  University of Manchester - NOWGEN, United Kingdom 
Kay Warner  GlaxoSmithKline, United Kingdom 
Niels Westergaard BIOPEOPLE, University of Copenhagen, Denmark 
Kim Wever  European Genetic Alliance Network (EGAN)/Dutch Genetic Alliance (VSOP), The Netherlands 




Hilton Rome Airport Hotel 
Room: Salone dei Cesari 
Via Arturo Ferrarin 2 Fiumicino 
00054 Rome - Italy  
Tel: +39-06-65258 - Fax: +39-06-6525 6525 








For further information about 
- The Project: please visit www.patientsacademy.eu or contact the EUPATI secretariat - Tel: +49 89 660 869 68  
E-mail: info@patientsacademy.eu 
- Participation in the Workshop and in the EUPATI Network: contact the EFGCP Secretariat -Tel: +32 2 732 87 83 
E-mail: eupati@efgcp.eu 
 
For more information, please click on the following link: EUPATI: A Vision for 2020. 
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AGENDA 
 
THURSDAY, 18 APRIL 2013 
19:00 – 22:00  Welcome Dining Reception  
(Giardino dei Consoli Room) 
 
FRIDAY, 19 APRIL 2013 
 
07:45  Registration & Welcome Coffee  
08:30  Welcome and Introduction 
  Anders Olauson, European Patients’ Forum (EPF), Sweden 
08:35  Patients at the core of European healthcare research: the IMI perspective 
  Michel Goldman, Innovative Medicines Initiative (IMI) 




Patient involvement in medicines R&D Process in 2020   
How to progress the involvement of patients in the process of medicines development has long been debated. The 
ultimate goal of EUPATI is to provide dedicated training, information and material to equip and empower more 
patients to become active partners with academia, industry, regulatory agencies, HTA bodies and ethics committees. 
This session will set the scene for this step change in approach by sharing examples of current best practice and 
encourage an exchange of views on how EUPATI can be a catalyst for efficient patient involvement in new treatment 
development processes across Europe.   
 
Co-chairs:  Virginie Delwart, Janssen, Belgium & David Haerry, European Aids Treatment Group (EATG), 
Switzerland  
09:15   Vision – here we are, where we want to be in 2020  
  Nicola Bedlington, European Patients’ Forum (EPF), Belgium 
09:35  Best practices  
  ’DAWN2 Study’ - Soren Skovlund, Novo Nordisk, Denmark 
  ‘Collaboration as the best practice: All Together now!’ - Filippo Buccella, Parent Project Onlus, Italy 
  Abstract Presentations 
  ‘EATG Advisory Group’ - David Haerry, European Aids Treatment Group (EATG), Switzerland 
‘Young People’s Involvement in Medicines R&D’ - Jennifer Newman, NIHR Medicines for Children 
Research Network, United Kingdom 
10:05  Bring to life with EUPATI examples  
  Jan Geissler, European Patients’ Forum (EPF), Germany 
10:20  Open discussion on how to achieve the vision  
11:10  Coffee Break & Posters Presentation 
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SESSION 2: 
Building Knowledge & Competences for Patients’ Involvement in Medicines R&D   
Educating and training patients objectively, efficiently and adapted to their needs in the complex area of medicines 
research and development requires to take new avenues.  Different innovative approaches how to teach a lay 
audience need to be considered.  EUPATI chose the strategic approach of training knowledgeable patient 
representatives as experts, as well as providing suitable educational material and toolkits for own use with their 
constituency and local partners. This session will explore best practice examples on patient education pursued by 
other stakeholders, and discuss which lessons can be learned for EUPATI to facilitate effective and meaningful 
involvement of patients in R&D. 
Co-chairs:  Bella Starling, University of Manchester - NOWGEN, United Kingdom & Nancy Hamilton, European 
  Organisation for Rare Diseases (EURORDIS), France 
11:30   Vision – here we are, where we want to be in 2020  
  Ingrid Klingmann, European Forum for Good Clinical Practice (EFGCP), Belgium 
11:50  Best practices  
  Svilen Konov, European Aids Treatment Group  (EATG), Belgium  
  Abstract Presentations 
  ‘Essential principles for training and support for public involvement in research’ - Lucy Simons, 
  INVOLVE /University of Leeds, United Kingdom 
  ‘Patients’ perception of the “informed consent”’ - Elizabeta Zisovska, University Clinic for Gynecology 
  and Obstetrics, Macedonia  
12:20  Bring to life with EUPATI examples 
  Niels Westergaard, BIOPEOPLE, University of Copenhagen, Denmark 
12:35  Open discussion on how to achieve the vision  




Public awareness about new medicines development in 2020  
 
Pharmaceutical medicines development is a highly regulated, costly, long and complex process that is largely 
unknown to the lay public. Benefits and risks of existing and new treatment alternatives are difficult to understand for 
the general public. In an era of growing demand and emphasis on both quality and sustainability of healthcare, it is 
critical to address this major gap in public perception and knowledge.  
This session will explore how EUPATI can contribute to overcome current barriers through a coordinated approach of 
all stakeholders involved in this process and to develop reliable and most up-to-date information and opportunities for 
involvement of the lay patients and citizens. 
Co-chairs:  Matthias Gottwald, Bayer Pharma, Germany & Kim Wever, European Genetic Alliance Network 
(EGAN)/Dutch Genetic Alliance (VSOP), The Netherlands 
14:30   Vision – here we are, where we want to be in 2020  
  Peter O’Donnell, Journalist, Belgium 
14:50  Best practices  
  Paola Mosconi, Istituto di Ricerche Farmacologiche Mario Negri, Italy 
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  Abstract Presentations 
  ’The benefits of benefits: A qualitative study exploring opinions on the inclusion of benefit information 
  about medicines in PILs’ - Rebecca Dickinson, University of Leeds, United Kingdom 
  ‘User Testing of an EPAR Summary – Does it meet people’s needs?’ – Dave Bryant, Luto Research, 
  United Kingdom 
15:20  Bring to life with EUPATI examples  
  Barbara Haake, Die forschenden Pharma-Unternehmen (vfa), Germany 
15:35  Open discussion on how to achieve the vision  
16:30  Closing discussion: achieving goals    
  Nicola Bedlington, European Patients’ Forum (EPF), Belgium & Kay Warner, GlaxoSmithKline, United 
  Kingdom 





        
The EUPATI project receives support from the European Union (IMI JU) and EFPIA companies 
